Paper Details

  1. Home
  2. Paper Details

Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.

Author: BartelsH, BartlR, BraunH J, ColdeweyR, DeicherH, FischerJ T, GramatzkiM, LeoR, PeestD, von BroenI M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 277 patients with multiple myeloma found that VBAMDex treatment was more effective than MivP in achieving remission for stage III patients. For stage II patients with progressive disease, MivP treatment led to remission in 61% of cases. Interferon-alpha maintenance therapy was not effective in preventing relapse in stage II and III patients with stable disease. Survival rates were higher for stage II patients compared to stage III patients.
Paper Details　
Original Abstract of the Article :
277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n = 14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000216820

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma: A Desert of Uncertainties

Multiple myeloma, a complex and challenging blood cancer, is like a shifting sand dune in the desert of oncology. This research investigates two different induction chemotherapy regimens, melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex), followed by interferon maintenance treatment in patients with multiple myeloma. The study aims to compare the efficacy of these treatment approaches in achieving remission and improving overall survival. The study provides valuable insights into the complexities of treating multiple myeloma, highlighting the importance of choosing the right treatment strategy for each patient.

Navigating the Desert of Myeloma: Comparing Treatment Regimens

The study reveals that VBAMDex induction chemotherapy led to a higher response rate compared to MP, suggesting a potential benefit in terms of achieving remission. This finding underscores the importance of considering different treatment options for multiple myeloma, like carefully choosing the right camel for a journey through the desert. The study also found that interferon maintenance therapy did not significantly impact relapse rates, suggesting that further investigation is needed to determine its role in managing this complex disease.

A Desert Oasis of Hope: Continued Research and Personalized Treatment

This research highlights the ongoing challenges of treating multiple myeloma, a disease that requires a multifaceted approach to management. The study emphasizes the need for continued research into more effective treatment strategies, including new drugs and combinations of therapies. It also underscores the importance of personalized medicine, tailoring treatment plans to meet the unique needs of each patient.

Dr. Camel's Conclusion

Multiple myeloma is a complex and challenging disease, like a vast and shifting desert. This research offers valuable insights into different treatment strategies, highlighting the importance of choosing the right approach for each patient. The study emphasizes the need for continued research and innovation to develop more effective treatments and improve outcomes for patients with this challenging disease.

Date :
  1. Date Completed 1991-06-13
  2. Date Revised 2018-02-16
Further Info :

Pubmed ID

2092283

DOI: Digital Object Identifier

10.1159/000216820

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.